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Pulmonary hypertensionAbstract Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease
of unknown etiology. It is possible that lifestyle-related diseases may affect either the initiation or
progression of IPF. Comprehensive data are lacking from Egypt. The aim of the study was to inves-
tigate the following hypothesis that lifestyle-related diseases may increase the risk of development of
IPF; and augment the risk of progression and development of pulmonary hypertension (PH) in IPF
patients.
Study design: A case approach prospective study.
Methods: A total of 92 patients with IPF were included in the study. Sixty-seven were females
and 25 cases were males, their age ranged from 14 to 82 years. Detailed medical history, clinical
manifestations, laboratory and radiological findings, cardiac and pulmonary assessments were
recorded and compared with the diagnostic criteria for lifestyle-related diseases.
Results: The adjusted OR of GERD was 0.48 (95% confidence interval [CI], 0.13–1.71), the
adjusted OR for DM was 0.12 (95% CI, 0.03–0.56) and the adjusted OR for hyperlipidemia was
0.30 (95% CI, 0.07–1.27). There were no differences between the clinical characteristics of patients
with IPF and PH and patients with IPF without PH that could be related to life style related
diseases.
Conclusion: Lifestyle related diseases may be a risk factor for IPF. IPF patients are more often
slightly younger, obese and females. However, there was no prevalence of any of those diseases in
IPF patients with PH as PH is considered a prognostic indicator of IPF.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Idiopathic pulmonary fibrosis (IPF) is considered a major sub-
type of idiopathic interstitial pneumonias according to the
American Thoracic Society (ATS)/European Respiratory
Society (ERS) International Multidisciplinary Consensusrculosis.
128 S. Kaddah, S. AhmedClassification of idiopathic interstitial pneumonias [1]. It is
defined as ‘‘a specific form of chronic, progressive, fibrosing
interstitial pneumonia of unknown cause, occurring primarily
in older adults, limited to the lungs, and is associated with
the histopathological and/or radiological pattern of usual
interstitial pneumonia” [1].
IPF has a poor predictable clinical course with an increased
mortality rate [2]. Clinical and demographic data on IPF show
substantial differences in different world regions [3].
Worldwide, the prevalence estimates for IPF range from 6 to
32 per 100,000 [4]. Comprehensive data are lacking from
Egypt and the Middle East. However, a study from Saudi
Arabia included 330 patients with intestinal lung diseases
(ILD), out of which 23% had IPF [5]. Patients with IPF are
usually between 50 and 70 years of age and symptoms typically
presenting 2–4 years before the onset of the disease. The most
common presenting symptoms of IPF are dry cough and mod-
erate to severe dyspnea on exertion [2,4].
Several epidemiologic studies show the potential risk of
cigarette smoking [6,7], associated comorbidities such as gas-
troesophageal reflux disease (GERD) [8–10] and ischemic
heart disease (IHD) [11,12] and occupational dust exposure
as a confound factor(s) to the progression of IPF [6,13,14].
Also, lifestyle-related diseases, such as obesity, hypertension,
diabetes mellitus (DM), hyperlipidemia, and hyperuricemia
are an important contributing factor(s) that may affect the ini-
tiation or progression of IPF [15,16].
Pulmonary hypertension (PH) is a common complication of
IPF and may be found in patients with preserved lung func-
tion. As the symptoms of PH in IPF are nonspecific, the devel-
opment of PH in a patient with IPF can be easily overlooked.
Possible pathogenic mechanisms of PH in IPF include vascular
destruction, pulmonary hypoxic vasoconstriction and vascular
remodeling due to overexpression of cytokines and growth fac-
tors. Several studies show that IPF patients with PH have
decreased exercise capacity and a worse prognosis [17,18]. So
it is important to investigate for PH in these patients due to
its prognostic significance. Doppler echocardiography is a
useful noninvasive tool for the detection of PH. However, right
heart catheterization remains the gold standard diagnostic
test [17].Patients and methods
Study design
A case approach, prospective study during the period from
January 2013 to January 2015 approved by the Human
Ethics Committee of Cairo University, included all
IPF patients admitted to the chest diseases department, Kasr
Al-Aini Hospital, Cairo University and Embaba Chest
Hospital. All subjects gave informed consent to the study.
Diagnosis of IPF was made when the patient met the crite-
ria corresponding to the international consensus statement of
IPF of the American Thoracic Society (ATS)/European
Respiratory Society (ERS)/Japanese Respiratory Society
(JRS)/Latin American Thoracic Association (ALAT) recom-
mendations [1]. They stated that the major and minor criteria
proposed in ATS/ERS (2000) consensus statement [19] have
been eliminated and mentioned that the diagnosis of IPF
requires the following:1. Exclusion of other known causes of ILD (e.g., domestic and
occupational environmental exposures, connective tissue
disease and drug toxicity).
2. The presence of a UIP pattern on HRCT in patients not
subjected to surgical lung biopsy.
3. Specific combinations of HRCT and surgical lung biopsy
pattern in patients subjected to surgical lung biopsy.
The aim of the study was to investigate the following
hypothesis that age, sex, occupational and environmental
exposure to birds, cigarette smoking and/or lifestyle associated
diseases, such as obesity, GERD, arterial hypertension,
ischemic heart disease (IHD), diabetes mellitus (DM), hyper-
lipidemia, and hyperuricemia may increase the risk of develop-
ment of IPF; and augment the risk of progression and
development of pulmonary hypertension (PH) in IPF patients.
The following data were collected:
 Clinical data including sex, age, body mass index (BMI),
duration of illness, occupational history, history of raising
birds, smoking status and the presence of co-morbidities
e.g., IHD, DM, GERD, arterial hypertension, hyperlipi-
demia, hyperuricemia were recruited.
 Measurements of arterial blood pressure.
 Results of Laboratory findings including total leukocyte
count (TLC), plasma level of C-reactive protein (CRP),
fasting blood sugar (FBS), lactate dehydrogenase (LDH),
total cholesterol (T-chol), triglycerides and uric acid (UA)
levels.
 Serological blood tests to rule out UIP associated collagen
vascular diseases.
 Results of pulmonary function tests including spirometry
measurements (forced expiratory volume in the first
second/forced vital capacity (FEV1/FVC) ratio, FVC
(% predicted value), FEV1 (% predicted value), forced
expiratory flow FEF 25–75% (% predicted value) and
6-Minute Walk Test (6-MWT)).
 Results of arterial blood gas measurements.
 High resolution computed tomography of the chest
(HRCT) to declare the typical pattern of UIP.
 Findings of electrocardiograms and echocardiograms.
 Results of pathological confirmation of UIP pattern either
by video-assisted medical thoracoscopic lung biopsy or
open lung biopsy whenever possible.
Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), median, range, frequencies (number of
cases) and/or percentages when appropriate. Comparison of
numerical variables between the study groups was done using
Student t test for independent samples. For comparing cate-
gorical data, Pearson Chi square (v2) test was performed.
Exact test was used instead when the expected frequency is less
than 5. Multivariate logistic regression analysis models were
used to test for the preferential effect of the independent vari-
able(s) on the occurrence of pulmonary hypertension. P values
less than 0.05 were considered statistically significant. All sta-
tistical calculations were done using computer program SPSS
(Statistical Package for the Social Science; SPSS Inc.,
Chicago, IL, USA) release 15 for Microsoft Windows (2006).
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Our study included 102 patients, 92 patients were diagnosed
with IPF, and 10 patients were excluded due to associated col-
lagen vascular disease diagnosed by positive medical history,
clinical examination and positive autoimmune tests. The
diagnosis of IPF was based on the absence of an indictable
etiology for ILD by clinical history and examination, the pres-
ence of the typical radiological pattern of UIP on HRCT scans
of the chest and/or the pathological results of either video-
assisted medical thoracoscopic lung biopsy or open lung
biopsy. There were fifteen cases with positive histopathological
confirmation, 9 cases were diagnosed by video-assisted medical
thoracoscopic lung biopsy and 6 cases were diagnosed by open
lung biopsy. The results of pulmonary function tests were also
used to assist the diagnosis.Table 1 Co morbidity, laboratory and radiological findings in
patients at initial presentation.
Parameter Number
(Percentage)
Class I obesity 17 (18.5)
Class II obesity 11 (12)
Class III obesity 2 (2.2)
Normal weight 31 (33.7)
Overweight 30 (32.6)
Underweight 1 (1.1)
GERD 31 (33.7)
Diabetes 21 (22.8)
Arterial hypertension 24 (26.1)
IHD 8 (8.7)
Hyperlipidemia 20 (21.7)
Hyperuricemia 16 (17.4)
Pulmonary hypertension 52 (56.5)
Elevated CRP level 30 (32.6)
Leukocytosis 38 (41.3)
Elevated LDH level 82 (89.1)
Radiological HRCT findings
 Bilateral extensive fibrosis with
honeycombing
(31.5)
 Bilateral reticulonodular infiltration with
traction bronchiectasis
63 (68.5)
Table 2 Respiratory and cardiac testing at baseline.
Parameter
PH
PaCO2 mmHg
PaO2 mmHg
SO2 %
FiO2 %
FEV1 (% predicted)
FVC (% predicted)
FEV1/FVC
FEF 25–75 (% predicted)
Pulmonary artery systolic pressure via echocardiography (mmHg)
6 MWD (m)The patients were predominantly females (67 patients,
72.8%) and all were house wives. There were 25 male patients
(27.2%); their occupational histories were 7 workers in wood
industry, 5 cases were working in a petrochemical factory, 4
cases were working in agriculture, 4 cases were employees, 2
cases were working in a sugar factory, 2 builders and a single
case the patient was a physician.
Most of our patients were overweight with mean BMI
27.98 ± 5.8 kg/m2 and 30 patients were diagnosed with obe-
sity. Their age ranged from 14 to 82 years (50.7 ± 13.9 years),
the duration of illness ranged from 6 months to 22 years (5.9
± 4.6 years) and 31 patients (33.7%) were on home oxygen
at presentation.
There were 22 (23.9%) female patients raising birds and 17
(18.5%) male patients with positive smoking history. Patients’
co-morbidity, laboratory and radiological findings are shown
in Table 1. All patients had progressive dyspnea on exertion
and basal fine crackles by auscultation. They had moderate
reduction in FVC and FEV1 and showed restrictive pattern
in spirometry. Respiratory and cardiac testing of our patients
is shown in Table 2.
There were 52 IPF patients with pulmonary hypertension.
They had PH via echocardiography. Comparisons of the clin-
ical characteristics, respiratory and cardiac testing between
IPF patients with and without pulmonary hypertension are
shown in Tables 3 and 4.
Discussion
In Egypt, little attention has been paid to confirm the role of
age, sex, occupational and environmental exposure, cigarette
smoking and/or lifestyle associated diseases, such as obesity,
arterial hypertension, IHD, DM, GERD, hyperlipidemia,
and hyperuricemia in the disease development of IPF; and
the effect of these factors in influencing the development and
progression of PH in those patients. The identification of risk
factors for IPF is critically important as it may inform preven-
tion strategies, early diagnosis, and novel therapies. In our
study we tried to investigate those associations and IPF
prospectively.
It is clear that the prevalence and incidence of IPF are
higher in older age groups, however in our study, the mean
age of IPF patients was 50 ± 13 years, their mean BMI was
27 ± 5 kg/m2 among them 30 (32.6%) patients were diagnosedNo. (%) Mean ± SD Range
92 (100) 7.4 ± 0.04 7.3–7.6
92 (100) 38.4 ± 7.5 20–63
92 (100) 60.6 ± 16.9 35–117
92 (100) 88.7 ± 6.9 70–99
92 (100) 24.9 ± 6.15 21–44
92 (100) 54.0 ± 23.3 22–124
92 (100) 53.5 ± 22.5 22–145
92 (100) 94.6 ± 13.3 66–121
92 (100) 48.9 ± 23.3 10–153
92(100) 58.8 ± 18.9 30–100
92 (100) 254.6 ± 114.6 50–575
Table 3 Comparison between the clinical characteristics of
IPF patients with and without PH.
Characteristics IPF patients
with PH
(n= 52)
IPF patients
without PH
(n= 40)
P
value
Age/yr 49.85 (15.45) 51.80 (11.71) 0.507
Female/male ratio 36/16 31/9 0.377
History of raising birds 11 11 0.479
Smoking history 9 8 0.742
Duration of illness/yr 5.66 (4.30) 6.16 (4.92) 0.605
BMI 28.56 (6.10) 27.22 (5.50) 0.605
Class I obesity 11 6
Class II obesity 6 5
Class III obesity 2 0
Normal weight 16 15
Over weight 17 13
Under weight 0 1
Associated comorbidity
GERD 14 17 0.117
Diabetes 9 12 0.150
Arterial hypertension 13 11 0.787
IHD 4 4 0.697
Hyperlipidemia 12 8 0.723
Hyperuricemia 9 7 0.659
Elevated CRP level 17 13 0.984
Leukocytosis 20 18 0.528
Elevated LDH level 45 37 0.362
Predominant HRCT Pattern
Bilateral extensive fibrosis
with honeycombing
20 9 0.184
Bilateral reticulonodular
infiltration with traction
bronchiectasis
32 31
Values of age, duration of illness and BMI are expressed as mean
(standard deviation).
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obesity. Our findings were not going hand in hand with a study
conducted by Sherbini et al., which included 134 IPF patients
from Saudi Arabia, the mean age and BMI of their patients
were 64 ± 13 years and 29 ± 8 kg/m2 respectively [20]. Also,
our results disagreed with those of a Japanese study; con-
ducted by Enomoto et al., where, most of their patients were
old age (the mean age of their patients was 65.4 years) and
their mean BMI was 22.5 kg/m2 (19.2% of them were diag-
nosed as obese) [16]. The relatively old age of IPF patients is
a finding consistent with the role of aging in the pathogenesis
of IPF [21]. Also, the prevalence of a high BMI among them
could be explained by steroid use that induced salt and water
retention or; as in several studies that excluded IPF patients,
which had received steroid therapy and reported an association
between obesity and IPF as adipose cells may play a role in
epithelial cell injury [22,23]. However there are other studies
that associated high BMI with a good prognosis of IPF [24,25].
In several studies, IPF appears to be more common in men
compared to women, some postulate that this may be due to
sex differences in historical smoking patterns rather than an
inherent sex-related risk for IPF [2,25]. However, in our study,
most of the IPF patients were females 72.8% and all of them
were non-smokers and house wives. Only 23.9% of the female
IPF patients gave history of raising birds. There were 25 maleIPF patients (27.2%), 18.5% gave history of cigarette smoking
and most of them; their occupational history included dust
and/or chemical exposure. Our results were matched with
those of Sherbini et al., where 56% of their patients were
females and 44% were males; however smoking among their
patients was more evident as 36% of IPF patients were smok-
ers compared to 18.5% smoking prevalence among our IPF
patients [20]. On the other hand, Enomoto et al., most of their
patients were males (female patients were 21.1%), and there
was a high prevalence of smoking history among their patients
(84.6%) [16]. It seems that smoking among our patients didn’t
play as much role as the other previous studies; however, more
recent studies showed that there is no significant association
between IPF and smoking status [10,23,26]. The female
predominance especially in the Middle East region may
indicate the possible role of genetic polymorphisms that needs
to be examined in further studies.
Also, the occupational history of our patients was similar to
a multicenter hospital-based case control study from 2010 to
2011 performed in Egypt where; Awadalla et al., found signif-
icant associations for occupations in woodworking and
chemical/petrochemical industry for men and raising birds
and farming for women and risk for development of IPF [27].
Our patients presented with a wide range of the duration of
illness from 6 months to 22 years with a mean of 5.9
± 4.6 years. Almost more than half of the IPF patients
(56.5%) had pulmonary hypertension and 33.7% were on
home oxygen at presentation. In Saudi Arabia, Sherbini
et al., showed that although 66% of their patients had slowly
progressive IPF, only 12% had PH and 53% of them were on
home oxygen at presentation [20]. They also stated that there
was a similitude between their results and other studies in
Saudi Arabia [5,28]. The difference between our results and
those of Sherbini et al., probably indicates delayed diagnosis
and referral of IPF patients to hospitals for proper
management.
GERD was relatively common in our IPF patients (31
cases, 33.7%), a finding supports the hypothesis that GERD
and chronic micro-aspirations increase the risk of IPF
[29–32]. However, an Egyptian study conducted by Embarak
et al., on 20 IPF patients confirmed the presence of abnormal
distal acid exposure in 85% of their IPF patients compared to
35% of 20 non IPF patients. The prevalence of GERD was
much higher among their patients. Also, they found a good
correlation between the degree of pulmonary fibrosis (HRCT
score) and the number of both distal and proximal reflux
episodes in IPF patients [33]. Therefore, those results reinforce
the potential role of GERD in the development and/or
progression of IPF and that GERD should be searched for
and properly treated to prevent its possible effect on pul-
monary fibrosis in IPF patients.
Twenty-one (22.8%) of the IPF patients had diabetes,
26.1% had arterial hypertension and 8.7% had IHD.
Sherbini et al., found that 42% of their IPF patients had dia-
betes and 39% had ischemic heart disease which were more
common in their cohort than in the general population [20].
A finding had been shown in several studies that the prevalence
of DM among IPF patients was significantly higher than in the
control groups. DM may increase the risk and pathogenesis of
IPF via oxidative stress lung damage that might be produced
by advanced glycation end products (AGEs) mediated by
hyperglycemia [16,23,34,35].
Table 4 Comparison of respiratory and cardiac testing between IPF patients with and without PH.
Parameter IPF patients (n= 92) Mean ± SD Range (P value)
PH With PH (n= 52) 7.43 ± 0.05 7.29–7.55 (0.397)
Without PH (n= 40) 7.42 ± 0.04 7.34–7.54
PaCO2 mmHg With PH (n= 52) 38.4 ± 8.13 23–63 (0.988)
Without PH (n= 40) 38.4 ± 6.61 20–56
PaO2 mmHg With PH (n= 52) 56.3 ± 14.6 35–90 (0.004)
*
Without PH (n= 40) 66.4 ± 18.3 38–117
SO2% With PH (n= 52) 86.9 ± 7.45 70–99 (0.003)
*
Without PH (n= 40) 90.9 ± 5.33 80–98
FiO2% With PH (n= 52) 26.4 ± 7.31 21–44 (0.005)
*
Without PH (n= 40) 22.9 ± 3.30 21–32
FEV1 (% predicted) With PH (n= 52) 54.6 ± 20.9 23–124 (0.804)
Without PH (n= 40) 53.4 ± 26.4 22–108
FVC (% predicted) With PH (n= 52) 53.7 ± 20.2 22–95 (0.927)
Without PH (n= 40) 53.3 ± 25.4 22–145
FEV1/FVC With PH (n= 52) 96.8 ± 13.2 76–121 (0.079)
Without PH (n= 40) 91.9 ± 13.0 66–119
FEF 25–75(% predicted) With PH (n= 52) 49.9 ± 22.0 14–153 (0.653)
Without PH (n= 40) 47.7 ± 25.1 10–153
Pulmonary artery systolic pressure via echocardiography (mmHg) With PH (n= 52) 58.8 ± 18.9 30–100
6 MWD (m) With PH (n= 52) 225.4 ± 109.9 50–575 (0.005)*
Without PH (n= 40) 292.4 ± 110.6 68–560
P values less than 0.05 were considered statistically significant.
* Means statistically significant P-value.
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demia, a finding similar to that of Enomoto et al., where
hyperlipidemia was present in 19.2% of their IPF patients vs
46% of the control group.[16] Also, Sherbini et al., stated that
11% of their IPF patients had dyslipidemia [20]. This finding
raises interest about the potential role of hyperlipidemia and
elevated levels of fatty acids and their role in increasing
oxidative stress via NADPH oxidase activation; that induce
pulmonary fibrosis and accelerate its progression due to
oxidant/anti-oxidant imbalance [36].
Hyperuricemia was present in 17.4% of our IPF patients
compared to 5.9% among IPF patients in Enomoto et al.,
study [16]. Uric acid is the final product of purine degradation
which increases markedly during hypoxia. Its elevated serum
level is associated with systemic inflammation and production
of inflammatory markers such as CRP and interleukin-6 [37].
Correlation between increased serum uric acid level and many
respiratory diseases such as COPD especially during exacerba-
tions, PH, obstructive sleep apnea and ARDS was reported in
several studies [38–41]. However, its role as a risk factor in IPF
needs further investigation.
Fifty-two patients of IPF had pulmonary hypertension, the
mean pulmonary artery systolic pressure via echocardiography
was 58.8 ± 18.9 mmHg. The impact of pulmonary hyperten-
sion on survival has been demonstrated in severe cases with
IPF and the higher MPAP and lower %FVC at the initial
evaluation were significant independent prognostic factors of
IPF [18].
In our study, we compared the impact of age, sex, environ-
mental exposure to birds among females, cigarette smoking
among males and even the duration of illness between IPF
patients who had PH and those without PH. They were all
non-significant. Also, when we studied the prevalence of life-
style associated diseases, such as obesity, GERD, arterial
hypertension, ischemic heart disease (IHD), diabetes mellitus
(DM), hyperlipidemia and hyperuricemia in IPF patients withPH, all were non-significant. To avoid the possibility of
confounding of every factor, we examined the adjusted OR
for the most common 3 factors by multivariate analysis. The
adjusted OR of GERD was 0.48 (95% CI, 0.13–1.71), the
adjusted OR for DM was 0.12 (95% CI, 0.03–0.56) and
the adjusted OR for hyperlipidemia was 0.30 (95% CI,
0.07–1.27). There were no differences between IPF patients
with PH and patients with IPF without PH.
Our laboratory findings revealed the presence of elevated
serum level of LDH in 89.1% of the IPF patients, leukocytosis
in 41.3% and elevated serum CRP level in 32.6%. Also,
Enomoto et al., found a highly significant (P-value < 0.001)
increase in the total leukocytic count, serum levels of LDH
and CRP in IPF patients compared to the control group
[16]. CRP is an acute phase protein produced primarily from
the liver and is stimulated by the release of cytokines, such
as interleukin-6 [42]. CRP is a marker of systemic inflamma-
tion that is elevated during a wide variety of diseases [43].
Several in vitro and animal model studies have suggested that
CRP may play a pathogenic role by inhibiting neutrophil
chemotaxis or modulating vascular permeability in ways that
could potentially be protective in the disease process [44–46].
CRP appears to play an important role in neutrophil chemo-
taxis, but its role may be more complex as CRP stimulates
chemotaxis at lower concentrations but inhibits it, along with
other characteristic neutrophil functions, at higher concentra-
tions [47–49]. However, we didn’t find a significant difference
in the laboratory findings in IPF patients with PH and those
without PH. The role of elevated serum CRP levels and leuko-
cytic functions whether they potentially increase the risk and/or
the progression of IPF or they may play a protective role at high
concentrations in patients with IPF needs further studies.
Some authors suggest that LDH is a potential marker of
disease activity and of response to therapy in different forms
of ILD [50,51]. Cytoplasmatic enzymes, like LDH, when pre-
sent in the extracellular space are indicators of cell damage
132 S. Kaddah, S. Ahmedor cell death. Serum LDH is a sensitive marker for cell injury,
but is a non-specific test since the concentration is elevated in
different circumstances of cell injury caused by ischemia, as by
excess heat or cold, starvation, dehydration, injury, exposure
to bacterial toxins, after ingestion of certain drugs, and from
chemical poisonings [51]. Consequently, we didn’t find a signif-
icant difference in the laboratory findings of serum LDH level
in IPF patients with PH and those without PH as serum LDH
is difficult to be used as a valid biomarker of disease activity in
ILD since its concentration is defined by many factors.
Several studies showed that the BMI, FVC%, DLCO%,
baseline PaO2, modified Medical Research Council score,
6-min walk distance, and lowest SpO2 of the 6-min walk test
were significantly predictive of survival in patients with IPF
[18,52,53].
Although, when we compared the adjusted OR of the pre-
dominant radiological findings 1.14 (95% CI, 0.62–2.09), and
the mean FVC% predicted (53.7 ± 20.2 vs 53.3 ± 25.4), there
was no difference between IPF patients with PH and those
without PH. However, when we compared the adjusted OR
of the PaO2 measured by ABGs 0.92 (95% CI, 0.85–1.01)
and the adjusted OR of the 6-min walk 1.00 (95% CI,
0.99–1.01), there was a significant difference between the two
groups. The current results suggest the importance of initial
evaluation and follow up of PH for IPF patients. However;
it also showed that the BMI and FVC% had no significant pre-
dictive value among our IPF patients with PH and the only
variant that had significance was the 6-min walk test.
Conclusion
IPF patients are more often slightly younger, obese and
females. Only 17 patients were smokers, they all were males.
Occupational hazards among wood and chemical/petrochemi-
cal industries for men and raising birds and farming for
women might be risk factors for development of IPF.
Lifestyle associated diseases, such as obesity, GERD, arterial
hypertension, ischemic heart disease (IHD), diabetes mellitus
(DM), hyperlipidemia, and hyperuricemia may influence the
risk of development of IPF; a finding like the epidemiological
estimates from other studies. However, none of the previous
factors have showed any impact on disease progression of
IPF, as there was no prevalence of any of those independent
factors on IPF patients with PH as PH is considered a prog-
nostic indicator of IPF.
Our results may enhance the understanding of the natural
history of IPF, strongly encourages more clinical evaluation
for early diagnosis and management of PH in those patients.
Research on new approaches to recognize and re-evaluate
those patients for proper management is required.
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